Technical Analysis for GRFS - Grifols, S.A.

Grade Last Price % Change Price Change
grade A 22.12 -0.14% -0.03
GRFS closed down 0.14 percent on Friday, July 19, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical GRFS trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish -0.14%
Pocket Pivot Bullish Swing Setup -0.14%
New 52 Week High Strength -0.14%
Overbought Stochastic Strength -0.14%
Up 3 Days in a Row Strength -0.14%
Up 4 Days in a Row Strength -0.14%
Shooting Star Candlestick Bearish 0.77%
Lizard Bearish Bearish Day Trade Setup 0.77%
Golden Cross Bullish 0.77%

Older signals for GRFS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Healthcare Providers Antibody Nutrition Products End Products European Union Hemophilia Transfusion Medicine Ibex 35 In Vitro Diagnostics Plasma Products
Is GRFS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.5
52 Week Low 17.42
Average Volume 1,505,526
200-Day Moving Average 19.5079
50-Day Moving Average 19.6482
20-Day Moving Average 21.247
10-Day Moving Average 21.816
Average True Range 0.3972
ADX 42.22
+DI 38.3423
-DI 11.3897
Chandelier Exit (Long, 3 ATRs ) 21.3084
Chandelier Exit (Short, 3 ATRs ) 20.7016
Upper Bollinger Band 22.7069
Lower Bollinger Band 19.7871
Percent B (%b) 0.8
BandWidth 13.742175
MACD Line 0.6768
MACD Signal Line 0.6752
MACD Histogram 0.0016
Fundamentals Value
Market Cap 30.22 Billion
Num Shares 1.37 Billion
EPS 0.49
Price-to-Earnings (P/E) Ratio 45.14
Price-to-Sales 5.73
Price-to-Book 6.87
PEG Ratio 1.34
Dividend 0.33
Dividend Yield 1.49%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.54
Resistance 3 (R3) 22.53 22.39 22.47
Resistance 2 (R2) 22.39 22.28 22.39 22.45
Resistance 1 (R1) 22.25 22.21 22.18 22.26 22.42
Pivot Point 22.11 22.11 22.07 22.11 22.11
Support 1 (S1) 21.97 22.00 21.90 21.98 21.82
Support 2 (S2) 21.83 21.93 21.83 21.79
Support 3 (S3) 21.69 21.83 21.77
Support 4 (S4) 21.70